XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
1.730
+0.050 (2.98%)
At close: Nov 20, 2026, 4:00 PM EST
1.740
+0.010 (0.58%)
After-hours: Nov 20, 2026, 7:30 PM EST
XBiotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
52.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 4.01M | -14.38M | -78.20% |
| Dec 31, 2021 | 18.39M | -25.60M | -58.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
XBIT News
- 4 weeks ago - XBiotech elects Jan-Paul Simard to serve as co-CEO - TheFly
- 4 weeks ago - XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers - GlobeNewsWire
- 4 weeks ago - XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer - GlobeNewsWire
- 5 months ago - XBiotech to enroll patients in vilamakitug trial following FDA review - TheFly
- 5 months ago - XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - GlobeNewsWire
- 1 year ago - XBiotech trading resumes - TheFly
- 1 year ago - XBiotech pauses rheumatology program - TheFly
- 1 year ago - XBiotech trading halted, news pending - TheFly